--- title: "HC Wainwright Reiterates \"Buy\" Rating for WAVE Life Sciences (NASDAQ:WVE)" description: "HC Wainwright has reiterated a \"buy\" rating for WAVE Life Sciences (NASDAQ:WVE) with a price target of $22.00, indicating a potential upside of 191.97%. The stock recently traded at $7.54, down $2.09," type: "news" locale: "en" url: "https://longbridge.com/en/news/256172717.md" published_at: "2025-09-05T16:58:45.000Z" --- # HC Wainwright Reiterates "Buy" Rating for WAVE Life Sciences (NASDAQ:WVE) > HC Wainwright has reiterated a "buy" rating for WAVE Life Sciences (NASDAQ:WVE) with a price target of $22.00, indicating a potential upside of 191.97%. The stock recently traded at $7.54, down $2.09, with a market cap of $1.20 billion. Analysts have mixed ratings, with 14 recommending "buy" and one "hold." The company reported a quarterly loss of $0.31 per share, missing estimates. Insider trading activity has seen significant share sales, and institutional investors have adjusted their stakes in the company. WAVE Life Sciences (NASDAQ:WVE - Get Free Report)'s stock had its "buy" rating reiterated by investment analysts at HC Wainwright in a research report issued on Wednesday,Benzinga reports. They currently have a $22.00 target price on the stock. HC Wainwright's price objective indicates a potential upside of 191.97% from the company's current price. - Wave Life Sciences Rockets 70% on Historic RNA Editing Success Several other research analysts have also recently weighed in on WVE. Oppenheimer assumed coverage on WAVE Life Sciences in a research note on Monday, July 28th. They issued an "outperform" rating and a $24.00 price target for the company. Wall Street Zen downgraded WAVE Life Sciences from a "hold" rating to a "sell" rating in a report on Friday, May 9th. Canaccord Genuity Group assumed coverage on WAVE Life Sciences in a research report on Monday, August 4th. They issued a "buy" rating and a $19.00 target price on the stock. Wedbush reissued an "outperform" rating and issued a $18.00 target price on shares of WAVE Life Sciences in a research report on Monday, June 23rd. Finally, Wells Fargo & Company dropped their target price on WAVE Life Sciences from $24.00 to $21.00 and set an "overweight" rating on the stock in a research report on Thursday, July 31st. Fourteen research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $20.27. Get **WAVE Life Sciences** alerts: **View Our Latest Research Report on WVE** ## WAVE Life Sciences Price Performance - Sarepta Therapeutics Inc.: Why it's a rising gene therapy star WAVE Life Sciences stock traded down $2.09 during trading hours on Wednesday, reaching $7.54. The company had a trading volume of 6,540,298 shares, compared to its average volume of 1,368,531. The firm has a market cap of $1.20 billion, a price-to-earnings ratio of -8.38 and a beta of -1.15. WAVE Life Sciences has a 12-month low of $5.04 and a 12-month high of $16.74. The company has a 50-day moving average price of $8.35 and a 200 day moving average price of $7.95. WAVE Life Sciences (NASDAQ:WVE - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.02). The company had revenue of $8.70 million during the quarter, compared to the consensus estimate of $11.52 million. As a group, research analysts expect that WAVE Life Sciences will post -1.14 earnings per share for the current year. ## Insiders Place Their Bets In other WAVE Life Sciences news, Director Christian O. Henry sold 9,670 shares of the firm's stock in a transaction on Wednesday, August 13th. The stock was sold at an average price of $8.81, for a total transaction of $85,192.70. Following the transaction, the director directly owned 29,645 shares in the company, valued at $261,172.45. This trade represents a 24.60% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Gregory L. Verdine sold 10,000 shares of WAVE Life Sciences stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $10.00, for a total value of $100,000.00. Following the completion of the transaction, the director owned 285,217 shares in the company, valued at $2,852,170. This represents a 3.39% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 271,893 shares of company stock valued at $2,631,568. Corporate insiders own 23.98% of the company's stock. ## Institutional Inflows and Outflows Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Adage Capital Partners GP L.L.C. lifted its position in WAVE Life Sciences by 30.1% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 12,516,500 shares of the company's stock worth $101,133,000 after acquiring an additional 2,894,396 shares during the period. Polar Capital Holdings Plc acquired a new position in shares of WAVE Life Sciences in the 4th quarter valued at about $12,370,000. MPM Bioimpact LLC lifted its holdings in shares of WAVE Life Sciences by 138.5% in the 4th quarter. MPM Bioimpact LLC now owns 1,489,237 shares of the company's stock valued at $18,422,000 after buying an additional 864,766 shares during the period. Loomis Sayles & Co. L P lifted its holdings in shares of WAVE Life Sciences by 35.3% in the 2nd quarter. Loomis Sayles & Co. L P now owns 3,295,700 shares of the company's stock valued at $21,422,000 after buying an additional 859,160 shares during the period. Finally, Driehaus Capital Management LLC lifted its holdings in shares of WAVE Life Sciences by 14.6% in the 4th quarter. Driehaus Capital Management LLC now owns 6,712,449 shares of the company's stock valued at $83,033,000 after buying an additional 853,589 shares during the period. 89.73% of the stock is currently owned by hedge funds and other institutional investors. ## About WAVE Life Sciences (Get Free Report) Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. ## See Also - Five stocks we like better than WAVE Life Sciences - NYSE Stocks Give Investors a Variety of Quality Options - IREN Is Up 186% YTD on AI Pivot—And It’s Just Getting Started - Buy P&G Now, Before It Sets A New All-Time High - Rocket Lab Strengthens Case for Breakout With New Launch Pad - The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number - Opera Limited Stock Set to End 2025 on a High Note *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.* ## Should You Invest $1,000 in WAVE Life Sciences Right Now? Before you consider WAVE Life Sciences, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and WAVE Life Sciences wasn't on the list. While WAVE Life Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [WVE.US - Wave Life Sciences](https://longbridge.com/en/quote/WVE.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | 美股盘中速递：目标价上调至 30 美元，WAVE 生命科学涨 12.27% | WAVE 生命科学涨 12.27%；礼来涨 0.36%，成交额达到 27.14 亿美元；默克涨 3.35%，成交额达到 11.61 亿美元；强生涨 0.75%，成交额达到 8.88 亿美元；阿斯利康涨 0.26%，市值达到 2841 亿美元 | [Link](https://longbridge.com/en/news/270530598.md) | | 荷兰国际集团 NV 迄今为止以平均价格€23.36 回购了 27,077,073 股 | ING Groep NV 已回购总计 27,077,073 股股票，平均价格为每股 23.36 欧元，作为其持续回购计划的一部分，总金额约为 632,457,091 欧元 | [Link](https://longbridge.com/en/news/275414222.md) | | 摩根士丹利公司生命科学房地产投资信托 - 表格 8.5（EPT/RI）- 生命科学房地产投资信托有限公司 | 摩根士丹利国际有限公司根据收购守则第 8.5 条披露了对生命科学房地产投资信托有限公司的交易。2026 年 2 月 10 日，他们以每股 0.4230 英镑至 0.4280 英镑的价格购买了 53,161 股普通股，并以每股 0.4280 | [Link](https://longbridge.com/en/news/275571270.md) | | 美股盘中速递：WAVE 生命科学涨 20.80%，CEO 演讲引发投资者热情 | WAVE 生命科学涨 20.80%；Alumis 涨 124.75%，成交额达到 7.46 亿美元；诺和诺德公司涨 4.60%，成交额达到 6.87 亿美元；礼来涨 2.38%，成交额达到 6.77 亿美元；强生涨 0.79%，市值达到 4 | [Link](https://longbridge.com/en/news/271671202.md) | | Bio-Rad 第四季度收入略超预期，主要得益于临床诊断部门的增长 | Bio-Rad 第四季度的收入增长了 3.9%，略微超过预期，主要得益于其临床诊断部门增长了 8.4%。生命科学部门由于学术研究资金减少，出现了 2.6% 的下滑。公司成功整合了 Stilla Technologies，增强了其 ddPCR | [Link](https://longbridge.com/en/news/275809784.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.